Trial Profile
Observational Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Sep 2022
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms REWARD
- Sponsors Amgen; Celgene Corporation
- 13 Jul 2022 Status changed from active, no longer recruiting to completed.
- 04 Jun 2022 Interim results ( as of 16 September 2021; n=98) assessing patients with psoriatic arthritis who received apremilast for 12 months, presented at the 23rd Annual Congress of the European League Against Rheumatism.
- 05 Jun 2021 Interim results (n=85; data cutoff date: 3 Nov 2020) presented at the 22nd Annual Congress of the European League Against Rheumatism